Topic: Valeant Pharmaceuticals International

Ezogabine, an Investigational Anti-Epileptic Drug, Receives Positive Vote from FDA Advisory Committee

Drugs.com - 559 days ago
GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration (FDA) advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.. "We are encouraged ...

Valeant Announces Presentation of Retigabine Data at the 8th European Congress on Epileptology

Drugs.com - 1254 days ago
VRX) announced today that clinical data for retigabine from the Phase III RESTORE program will be presented at the 8th European Congress on Epileptology, which will be held at the Berlin Internationales Congress Centrum (ICC) in Berlin, Germany, September 21-24, 2008.. Following ...

Valeant Announces Successful Completion of Retigabine Phase III Epilepsy Program Validating Novel Mechanism of Action

Drugs.com - 1380 days ago
VRX) today reported positive results for retigabine in RESTORE 2, the second of two Phase III pivotal trials, for this first-in-class neuronal potassium channel opener. RESTORE 2 evaluated the 600 and 900 mg daily doses of retigabine versus placebo in patients taking ...